Published in Gene Therapy Weekly, May 11th, 2006
Amigal is being developed as an oral therapy for the treatment of Fabry disease, a lysosomal storage disorder caused by an enzyme deficiency that leads to pain, kidney failure, and an increased risk of heart attack and stroke. Amigal is currently being studied in Phase II clinical trials in the U.S.,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.